MedTrace Logo

Axitinib + Ipilimumab in Advanced Melanoma

NCT04996823 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-12-04

No results posted yet for this study

Summary

The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.

Conditions

Interventions

DRUG

Ipilimumab

Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.

DRUG

Axitinib

Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Zeynep Eroglu, MD · Moffitt Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-04
Primary Completion
2026-08-20
Completion
2027-03-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04996823 on ClinicalTrials.gov